Program
Lamivudine
Also written as “Lamivudine/Zidovudine”, “Lamivudine (3TC)” and “lamivudine”.
Its studies are mostly in HIV Infections · Acquired Immunodeficiency Syndrome · Hepatitis B, Chronic · Infections · Hepatitis B, led by 5 companies.
Drug pageLamivudine: every studyMany companies study it; this page follows only the 49 they lead. All 239 studies, academic ones too, with its approvals and label.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| GlaxoSmithKlineits history only | 352 open or running | phase 4since Feb 15, 2000 | Nov 2, 1999 | Sep 14, 2032phase 3 · NCT07393659 |
| Bristol-Myers Squibb | 70 open or running | phase 4since Jun 27, 2005 | Nov 2, 1999 | none ahead |
| Abbottits history only | 40 open or running | phase 3since Nov 2, 1999 | Nov 2, 1999 | none ahead |
| Dupont Merckits history only | 20 open or running | phase 3since Nov 2, 1999 | Nov 2, 1999 | none ahead |
| Triangle Pharmaceuticalsits history only | 10 open or running | phase 3since Nov 2, 1999 | Nov 2, 1999 | none ahead |
Also a collaborator on its studies: PPD Development, LP and Dupont Applied Biosciences.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Bristol-Myers Squibb only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Nov 2, 1999First study: phase 3 study in HIV InfectionsFirst studyNCT00002371 · 80 enrolled · United States, Canada, Puerto Rico
- Mar 31, 2001Phase 3 study in HIV InfectionsNCT00013897 · United States, Austria, Belgium and more
- Jun 27, 2005Phase 4 study in HIV InfectionsNCT00116116 · 70 enrolled · United States
- Jun 28, 2005Phase 3 study in HIV InfectionsNCT00116298 · 900 enrolled · United States, Argentina, Belgium and more
- Aug 25, 2005Phase 3 study in HIV InfectionsNCT00135369 · 300 enrolled · United States, Puerto Rico
- Dec 11, 2006Phase 3 study in Hepatitis B, ChronicNCT00410202 · 629 enrolled · United States, Australia, Brazil and more
- Jun 13, 2012Phase 3 study in HIVNCT01620944 · 3 enrolled
TargetBeta
A vaccine: it acts on a pathogen, not a human gene.
“Human immunodeficiency virus type 1 reverse transcriptase inhibitor”ChEMBL 37, by rule
Studies
All 7 Bristol-Myers Squibb leads, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT01620944HIV | 3 | Terminated | Jan 22, 2013 | 3 |
| NCT00410202Hepatitis B, Chronic · United States, Australia, Brazil and more | 3 | Completed | Jan 2011 | 629 |
| NCT00135369HIV Infections · United States, Puerto Rico | 3 | Completed | Jul 2005 | 300 |
| NCT00116298HIV Infections · United States, Argentina, Belgium and more | 3 | Completed | Jan 2005 | 900 |
| NCT00116116HIV Infections · United States | 4 | Completed | Jun 2005 | 70 |
| NCT00013897HIV Infections · United States, Austria, Belgium and more | 3 | Completed | Apr 2003 | |
| NCT00002371HIV Infections · United States, Canada, Puerto Rico | 3 | Completed | Dec 1997 | 80 |
How it is read
Names in the registry
- “Lamivudine”, 35 entries
- “Lamivudine/Zidovudine”, 6 entries
- “Lamivudine (3TC)”, 4 entries
- “lamivudine”, 3 entries
- “DTG/3TC”, 2 entries
Conditions, from the studies’ own filings
- HIV Infections, 53 studies
- Acquired Immunodeficiency Syndrome, 8 studies
- Hepatitis B, Chronic, 6 studies
- Infections, 4 studies
- Hepatitis B, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.